Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?
AMY-101
Complement C3
Compstatins
Cp40
Hemodialysis
Thromboinflammation
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
09
11
2018
accepted:
19
11
2018
pubmed:
26
11
2018
medline:
29
10
2019
entrez:
26
11
2018
Statut:
ppublish
Résumé
Owing to an increasing shortage of donor organs, the majority of patients with end-stage kidney disease remains reliant on extracorporeal hemodialysis (HD) in order to counter the lifelong complications of a failing kidney. While HD remains a life-saving option for these patients, mounting evidence suggests that it also fuels a vicious cycle of thromboinflammation that can increase the risk of cardiovascular disease. During HD, blood-borne innate immune systems become inappropriately activated on the biomaterial surface, instigating proinflammatory reactions that can alter endothelial and vascular homeostasis. Complement activation, early during the HD process, has been shown to fuel a multitude of detrimental thromboinflammatory reactions that collectively contribute to patient morbidity. Here we discuss emerging aspects of complement's involvement in HD-induced inflammation and put forth the concept that targeted intervention at the level of C3 might constitute a promising therapeutic approach in HD patients.
Identifiants
pubmed: 30472267
pii: S1521-6616(18)30648-X
doi: 10.1016/j.clim.2018.11.010
pmc: PMC7366512
mid: NIHMS1605321
pii:
doi:
Substances chimiques
Complement C3
0
Complement Inactivating Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
102-105Subventions
Organisme : NIAID NIH HHS
ID : N01 AI030040
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI068730
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI030040
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Références
J Am Soc Nephrol. 2017 May;28(5):1622-1630
pubmed: 28057772
Blood. 2010 Jul 29;116(4):631-9
pubmed: 20424189
J Transl Med. 2016 Aug 05;14(1):236
pubmed: 27495980
Proteomics Clin Appl. 2010 Nov;4(10-11):829-38
pubmed: 21137026
Lancet. 2016 Jul 16;388(10041):294-306
pubmed: 27226132
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
Biomaterials. 1999 Oct;20(20):1959-67
pubmed: 10514074
Kidney Int. 1998 Apr;53(4):1044-51
pubmed: 9551416
J Immunol. 2011 Apr 1;186(7):4269-77
pubmed: 21339361
Kidney Int. 1983 Dec;24(6):764-9
pubmed: 6609269
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
J Clin Pathol. 1994 Feb;47(2):155-8
pubmed: 8132830
Nat Immunol. 2017 Nov 16;18(12):1288-1298
pubmed: 29144501
Immunobiology. 2015 Apr;220(4):476-82
pubmed: 25468722
Nat Rev Nephrol. 2017 May;13(5):285-296
pubmed: 28239169
Clin Kidney J. 2012 Oct;5(5):401-4
pubmed: 26019815
Adv Exp Med Biol. 2015;865:189-209
pubmed: 26306451
Clin Sci (Lond). 1990 Nov;79(5):471-6
pubmed: 2174314
Front Immunol. 2018 Jan 25;9:71
pubmed: 29422906
Adv Exp Med Biol. 2012;946:185-205
pubmed: 21948369
Mol Immunol. 2007 Jan;44(1-3):82-94
pubmed: 16905192
Adv Exp Med Biol. 2015;865:3-17
pubmed: 26306440
Front Immunol. 2018 Sep 13;9:2070
pubmed: 30271407
Nephron. 2016;132(1):5-14
pubmed: 26695077
Immunobiology. 2012 Nov;217(11):1097-105
pubmed: 22964235
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Kidney Int. 1989 Aug;36(2):257-65
pubmed: 2528653